Human Akt3 nucleic acid and uses thereof
View Patent ↗The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.
1. An in vitro method of inhibiting ASK1-induced cell death, the method comprising: 1) administering to a cell a composition comprising a nucleic acid encoding human Akt3 protein comprising SEQ ID NO: 2 and a human Src myristylation sequence; and 2) expressing said nucleic acid, wherein said human Src myristylation sequence is fused to the N-terminus of said Akt3 protein, wherein expression of Akt3 inhibits ASK1-induced cell death.
2. The method of claim 1 , wherein the cell death is cardiac cell death.
3. The method of claim 1 , wherein the cell death is cardiac myocyte death.
4. The method of claim 1 , wherein the nucleic acid is in a vector.
5. The method of claim 4 , wherein the vector is a plasmid.
6. The method of claim 4 , wherein the vector is a viral vector.
7. The method of claim 4 , wherein the viral vector is selected from the group consisting of retroviruses, adenoviruses, adeno-associated viruses, vaccinia virus and HSV virus.
8. The method of claim 1 , wherein the cell death is human embryonic kidney HEK293 cell death.